Eli Lilly has entered into a major, artificial intelligence-driven drug discovery collaboration with Insilico Medicine, valued at up to $2.75 billion. The partnership underscores Lilly’s continued push to integrate AI technologies into its research pipeline amid intensifying competition across high-growth therapeutic areas.
The agreement grants Lilly an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of novel oral therapeutics currently in preclinical development. These programs span multiple therapeutic areas and are designed using Insilico’s generative AI-driven drug discovery platforms.
The collaboration will also include joint research and development efforts, with both companies working across multiple programs focused on targets selected by Lilly. Insilico will contribute its Pharma.AI platform and automation capabilities, while Lilly brings its clinical development expertise and disease-area knowledge.
Financially, the deal includes an upfront payment of $115 million to Insilico, along with additional milestone payments tied to development, regulatory approvals, and commercialization. Total potential payments could reach approximately $2.75 billion, in addition to tiered royalties on any future product sales.
The partnership reflects a broader industry shift toward leveraging machine learning and AI to accelerate drug discovery timelines, reduce costs, and improve success rates in developing new therapies. For Insilico, the agreement represents a significant commercial milestone and further validation of its AI-first approach to pharmaceutical innovation.
KEY QUOTES:
“From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery. By deploying frontier AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time. Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health.”
Alex Zhavoronkov, Founder And CEO Of Insilico Medicine
“Insilico’s AI-enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development across multiple therapeutic areas. This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.”
Andrew Adams, Group Vice President Of Molecule Discovery At Eli Lilly
